Filing Details

Accession Number:
0001714899-23-000138
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-09-19 16:45:26
Reporting Period:
2023-09-15
Accepted Time:
2023-09-19 16:45:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1714899 Denali Therapeutics Inc. DNLI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1197020 L Vicki Sato C/O Denali Therapeutics Inc.
161 Oyster Point Blvd.
South San Francisco CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-09-15 1,626 $23.60 129,745 No 4 S Direct
Common Stock Disposition 2023-09-15 40 $24.35 129,705 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2023.
  2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.28 to $24.18 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $24.32 to $24.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  4. Includes 4,216 RSUs.